Amniotic Membrane for Diabetic Foot Ulcers: 2026 Clinical Evidence

Clinical Introduction

Diabetic foot ulcers (DFUs) affect an estimated 15% to 34% of patients with diabetes over their lifetime and precede roughly 85% of all non-traumatic lower-limb amputations. The intersection of peripheral neuropathy, arterial compromise, and impaired wound healing creates a clinical environment in which full-thickness ulcers frequently stall in a chronic inflammatory phase. Standard care — offloading, sharp debridement, infection control, and moist wound therapy — achieves complete closure in a minority of chronic, non-healing DFUs within the widely cited 12-week benchmark.

The human amniotic membrane (HAM) allograft has been studied as an adjunct to standard care across multiple randomized controlled trials and systematic reviews published between 2020 and 2026. The evidence has progressed from exploratory single-center studies to pooled meta-analyses encompassing more than 11 randomized trials. This article summarizes the published evidence for HAM in DFU management, including mechanism of action, clinical outcomes data, time-to-closure analyses, and comparison to standard wound care alone.

Mechanism of Action: Growth Factors and Microenvironment Modulation

Human amniotic membrane is a biological tissue composed of an epithelial monolayer, a basement membrane rich in extracellular matrix proteins, and an avascular stromal layer. It contains a complex profile of growth factors, cytokines, and tissue inhibitors of metalloproteinases (TIMPs) that may support wound healing through multiple pathways.

Koob and colleagues quantified the growth factor content in dehydrated human amnion/chorion membrane, identifying PDGF-AA, bFGF, TGF-β1, EGF, and multiple interleukins including IL-4, IL-6, IL-8, and IL-10. TIMP-1, TIMP-2, and TIMP-4 are also present. These factors are released in a sustained rather than bolus profile, with elution ranging from 4% (PDGF-BB) to 62% (EGF) into solution over the tested interval. This sustained-release pattern aligns with the chronic wound's need for prolonged signaling to reestablish autocrine and paracrine repair mechanisms that have been lost in the stalled wound environment.

The clinical relevance of the TIMP content is specific to DFU pathophysiology. Uncontrolled matrix metalloproteinase (MMP) activity is a hallmark of non-healing chronic wounds. Elevated MMPs degrade newly deposited extracellular matrix and perpetuate the inflammatory cycle. By contributing TIMPs, amniotic membrane may help rebalance the protease-antiprotease axis.

In-vitro studies have demonstrated dose-dependent increases in human dermal fibroblast proliferation in response to amniotic membrane extracts, along with directed mesenchymal stem cell migration. Anti-inflammatory cytokines including IL-10 have been detected at bioactive concentrations. Antimicrobial properties against multiple bacterial pathogens have been reported in laboratory models, although these findings have not been established as clinically significant in the setting of active wound infection.

Clinical Evidence: Meta-Analyses and Randomized Controlled Trials

A 2020 systematic review and meta-analysis by Haugh and colleagues included 7 randomized controlled trials involving 465 participants with chronic DFUs. The proportion of complete wound healing in the HAM plus standard-of-care (SOC) group was 3.88 times that of SOC alone at 6 weeks (RR: 3.88; 95% CI: 2.34–6.44) and 2.01 times at 12 weeks (RR: 2.01; 95% CI: 1.45–2.77). The number needed to treat within 6 weeks was 2.3 (95% CI: 1.8–3.1). The intervention group had a significantly shorter mean time to complete healing, with a mean difference of -30.33 days (95% CI: -37.95 to -22.72). No significant difference in adverse events was detected.

A 2022 meta-analysis by Momeni and colleagues extended these findings with 11 RCTs comparing DHACA plus SOC versus SOC alone, confirming superiority at 6 weeks (RR: 3.78; 95% CI: 2.51–5.70) and 12 weeks (RR: 2.00; 95% CI: 1.67–2.39), with greater wound size reduction in the DHACA group (MD: 1.18; 95% CI: -0.10–2.26; P = 0.03).

A 2024 systematic review and meta-analysis by Alomairi and colleagues, covering diabetic and venous ulcers, reported that HAM treatment demonstrated over 90% complete healing compared to standard care. Across pooled RCT data, the evidence base now includes approximately 500–600 randomized participants, and the direction of effect is consistent: amniotic membrane plus SOC produces higher closure rates and shorter healing times than SOC alone.

Selected Individual Trial Data

A randomized controlled trial of hypothermically stored amniotic membrane (HSAM) in 76 DFUs reported 12-week closure rates of 60% in the HSAM group versus 38% with SOC (P = 0.04), with a 75% increase in wound closure probability (HR: 1.75; 95% CI: 1.16–2.70). Greater than 60% area reduction occurred in 82% of HSAM wounds versus 58% of SOC (P = 0.02).

A 2021 prospective study of aseptically processed, dehydrated human amnion/chorion allograft reported a mean time to closure of 37 days versus 67 days with SOC within 12 weeks (P = 0.000006). A 2026 randomized comparative study of human amniotic membrane extract in DFUs reported a wound healing rate of 100% in the treatment group versus 77.5% in the control group at week 6. A 2025 randomized trial by Lavery and colleagues compared weekly versus biweekly application of AmnioExcel, providing practical data on application frequency in DFU management.

Comparison to Standard of Care

The SOC framework for DFU management — offloading, sharp debridement, moist wound therapy, infection management, and glycemic control — remains the foundation of treatment. Amniotic membrane allografts are positioned as an adjunct within this framework.

The published RCT data consistently show that HAM plus SOC outperforms SOC alone on both binary healing rates and time-to-closure endpoints. The relative benefit is largest in the first 6 weeks (approximately 3.8-fold increase in closure probability), with a smaller but still significant advantage at 12 weeks (approximately 2-fold increase). The absolute difference in closure rates remains clinically meaningful at 12 weeks across most trials.

No randomized trial has demonstrated superiority of one amniotic membrane format (cryopreserved, dehydrated, hypothermically stored) in head-to-head DFU comparison. Product selection is guided by handling characteristics, storage requirements, and clinician familiarity.

Active Clinical Trials (2026)

Several ongoing randomized trials registered on ClinicalTrials.gov are evaluating next-generation amniotic and placental membrane products for DFU management:

• NCT06565156 — BioREtain Amniotic Membrane (BR-AM) plus SOC in non-healing DFUs; multicenter, randomized, controlled
• NCT07116876 — Matrion placental membrane versus SOC for DFU closure
• NCT07116174 — Xcell Amnio weekly application for DFU healing
• NCT05024656 — AmnioExcel Plus (tri-layer placental allograft) versus SOC
• NCT07209475 — Amnio-Maxx effect on chronic DFU healing rate; multicenter RCT

Results are expected over the 2026-2028 period and may inform product selection, application frequency, and payer coverage criteria.

Key Takeaways

• Published meta-analyses demonstrate that HAM allografts plus standard care increase complete wound healing rates approximately 3.8-fold at 6 weeks and 2-fold at 12 weeks compared with standard care alone.
• Time-to-closure is reduced by approximately 12 to 30 days across pooled analyses, with mean healing times of 37-42 days in HAM-treated groups versus 67-72 days with SOC alone.
• The growth factor profile (PDGF-AA, bFGF, TGF-β1, EGF), cytokine content (IL-4, IL-6, IL-8, IL-10), and TIMP activity provide mechanistic support for the observed clinical effect.
• No head-to-head trial data currently distinguish cryopreserved, dehydrated, or hypothermically stored amniotic membrane formats for DFU outcomes. Product selection should be based on handling, storage, and protocol considerations.
• Multiple active randomized trials are evaluating new placental membrane products, with results expected over the next 12–24 months.

References

1. Haugh AM, Witt JG, Davidson EH, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials. Int Wound J. 2020;17(3):753-764. PMCID: PMC7949407.
2. Momeni M, Shayan N, Azimi Alamouti M, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? A systematic review and meta-analysis. Diabetol Metab Syndr. 2022;14(1):133. PMCID: PMC9472416.
3. Lavery LA, Suludere MA, Raspovic K, et al. Randomized Controlled Trial to Compare AmnioExcel Human Amniotic Allograft in Weekly Versus Biweekly Treatment of Diabetic Foot Ulcers. Int J Low Extrem Wounds. 2025 Jan 9. PMID: 39784000.
4. Alomairi AA, Alhatlani RA, Alharbi SM, et al. Assessing the Application and Effectiveness of Human Amniotic Membrane in the Management of Venous and Diabetic Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2024;16(3):e56659. PMCID: PMC11032220.
5. Azimi Alamouti M, Shayan N, Momeni M, et al. Human amniotic membrane extract for the management of diabetic foot ulcers: a randomised comparative study. J Wound Care. 2026;35(1):90-98. PMID: 41528793.
6. Koob TJ, Rennert R, Zabek N, et al. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J. 2013;10(5):493-500.
7. Serena TE, Yaakov R, Moore S, et al. A randomized controlled clinical trial of a hypothermically stored amniotic membrane for use in diabetic foot ulcers. J Comp Eff Res. 2020;9(1):23-34. PMID: 31691579.
8. Zelen CM, Serena TE, Denoziere G, et al. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J. 2013;10(5):502-507. PMID: 23742102.
9. Walters J, Cazzell S, Pham H, et al. Use of an aseptically processed, dehydrated human amnion and chorion allograft in the management of diabetic foot ulcers: a prospective, multicenter, randomized clinical trial. Wounds. 2021;33(2):37-45. PMCID: PMC7949511.
10. Margolis DJ, Morris LM, Nseyo O, et al. Systematic review on the rational use of amniotic membrane allografts in wound healing. J Wound Care. 2021;30(3):172-181. PMID: 33588807.